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Edited by Sandro SonninoAbstract Glycation of low-density lipoprotein (LDL) by reac-
tive aldehydes, such as glycolaldehyde, can result in the cellular
accumulation of cholesterol in macrophages. In this study, it is
shown that carnosine, or its constituent amino acids b-alanine
and L-histidine, can inhibit the modiﬁcation of LDL by glycolal-
dehyde when present at equimolar concentrations to the modify-
ing agent. This protective eﬀect was accompanied by inhibition of
cholesterol and cholesteryl ester accumulation in human mono-
cyte-derived macrophages incubated with the glycated LDL.
Thus, carnosine and its constituent amino acids may have thera-
peutic potential in preventing diabetes-induced atherosclerosis.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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People with diabetes have a 2-fold or greater risk of cardio-
vascular disease compared to control populations [1], with dia-
betes identiﬁed as an independent risk factor for
cardiovascular-associated mortality [2]. There is convincing
evidence that the hyperglycaemia characteristic of diabetes
contributes to the increased incidence of atherosclerosis. In
the recent follow up to the DCCT [3], it was shown that a per-
iod of intensive diabetes therapy directed towards attaining
normoglycaemia was associated a signiﬁcant reduction in car-
diovascular disease risk. A signiﬁcant reduction in HbA1c was
identiﬁed as a principal contributor to the reduction, although
notably the levels achieved were still the above current targets
of <7%. Thus, the development of therapies targeted at hyper-
glycaemia-induced damage remains a key treatment objective.
Glycation of proteins involves non-enzymatic reaction of a
sugar, or reactive aldehyde derived from these, with a nucleo-
philic group on the protein. The rate and extent of reaction is
dependent on the nature, concentration, and duration of expo-Abbreviations: AGE, advanced glycation end products; b-Ala, b-ala-
nine; CN, carnosine; GA, glycolaldehyde; His, histidine; HMDM,
human monocyte-derived macrophages; REM, relative electrophoretic
mobility
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doi:10.1016/j.febslet.2007.01.082sure to the modifying species. Aldehydes (e.g. methylglyoxal,
glyoxal and glycolaldehyde), formed via glucose autoxidation,
amino acid and lipid oxidation, and cellular metabolism, are
particularly potent glycating agents [4]. The plasma levels of
these aldehydes are increased in people with diabetes [5–7].
Glycation of amino acids leads to the generation of a heterog-
enous group of adducts known as advanced glycation end
products (AGE) [8]. Glucose and other aldehydes, both free
and protein-bound, can also undergo autoxidation (glycoxida-
tion) reactions that contribute to AGE formation [8,9].
Glycation reactions have been linked with the development
of diabetes-associated cardiovascular diseases [10]. We have
shown that ex vivo glycation of low-density lipoprotein
(LDL) induces intracellular cholesterol accumulation in mac-
rophages [11,12]. Such cholesterol-laden ‘‘foam cells’’ are a
hallmark of atherosclerosis and play a critical role in disease
development [13]. We therefore hypothesised that compounds
that inhibit protein glycation may prevent foam cell generation
and thus the development of diabetes-associated atherosclero-
sis.
Carnosine (b-alanyl-L-histidine) is an endogenous dipeptide
that can also be derived from the diet [14] or supplements [15].
It reacts rapidly with aldehydes, and can detoxify aldehyde-
modiﬁed proteins (reviewed [16,17]). Recently, Janssen and
colleagues [18] have identiﬁed an allele of the CDNP1 gene
for serum carnosinase, which hydrolyses carnosine, associated
with both a reduced serum enzyme activity and a reduced sus-
ceptibility to diabetic nephropathy. These ﬁndings support a
protective role for carnosine in the complications of diabetes.
The aim of the present study was to examine whether carno-
sine and its constituents inhibit LDL modiﬁcation induced
by glycolaldehyde, and whether this decreases the in vitro
accumulation of cholesterol and cholesterol esters in human
monocyte-derived macrophages (HMDM).2. Materials and methods
2.1. Materials
Reagents were obtained from the following sources. Sigma-Aldrich
(Castle Hill, NSW): b-alanine (b-Ala), BSA (fatty acid-free), carnosine,
EDTA, glycolaldehyde, Hanks Balanced Salt Solution (with phenol
red and 0.01% EDTA, but without Ca2+ and Mg2+), histidine (His),
PenStrep; Bio-Rad (Regents Park, NSW): Chelex-100 resin; Amer-
sham Biosciences (Castle Hill, NSW): PD10 columns; Helena Labora-
tories (Mt. Waverly, Vic): pre-cast 1% agarose gels. Axis-Shield (Oslo,
Norway): Lymphoprep; JRH Biosciences/CSL (North Ryde, NSW)
Trace Scientiﬁc (Melbourne, Vic): L-glutamine. All other chemicals
were of analytical grade, and all solvents were of HPLC grade.blished by Elsevier B.V. All rights reserved.
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lipore-Waters, Lane Cove, NSW) pre-treated with washed Chelex-100
resin to remove trace transition metal ions. Tissue culture reagents
used Baxter sterile water (Old Toongabbie, NSW, Australia) or PBS.
2.2. LDL modiﬁcations
LDL was isolated from normoglycaemic and normolipidaemic vol-
unteers [12] and glycated with 10 mM glycolaldehyde under conditions
previously described [12,19]. Incubation controls contained 50 lM
EDTA in place of glycolaldehyde. Carnosine, His, b-Ala or His + b-
Ala (all 10 mM) were added, prior to glycolaldehyde, and were present
throughout the modiﬁcation period. The added reagents (aldehydes or
EDTA, carnosine, b-Ala or histidine) were removed, by PD10 chroma-
tography, before addition of the modiﬁed LDL to cells.
2.3. Assessment of modiﬁcation of LDL
Changes in overall LDL particle charge were quantiﬁed by electro-
phoretic mobility on agarose gels [12].
2.4. Isolation and culture of human monocyte-derived macrophages
(HMDM)
Monocytes were isolated by counter-current elutriation from white
cell concentrates [20], then added (1 · 106/mL) to 12-well plates (Cost-
ar, Corning, NY) in serum-free RPMI 1640, and left to adhere for 1–
2 h. The cells were then washed and incubated (5% CO2 and 37 C) in
RPMI for 9–11 days to give HMDM [20].
2.5. Cellular cholesterol-loading studies
HMDM were exposed to modiﬁed or native LDL (100 lg/mL) in
media containing 10% lipoprotein-deﬁcient serum [21]. After 48 h, cell
media samples were collected, the cells washed with PBS, and lysed in
water. Cholesterol and cholesteryl ester concentrations was quantiﬁed
by HPLC [12]. Cell viability was determined by lactate dehydrogenase
release [12].
2.6. Protein assay
Protein concentrations were quantiﬁed using the Pierce (Rockford,
IL, USA) bicinchoninic acid (BCA) assay [12].
2.7. Data analysis
Data analysis was performed using one-way analysis of variance
using the Newman–Keuls multiple comparison test. P 6 0.05 was ta-
ken as signiﬁcant.3. Results
3.1. Characterisation and inhibition of LDL modiﬁcation
Incubation of LDL with 10 mM glycolaldehyde resulted in a
signiﬁcant increase in relative electrophoretic mobility (REM),
and thus an overall decrease in positive charge (Table 1). These
incubation conditions do not lead to a signiﬁcant oxidation of
the LDL as determined by consumption of a-tocopherol, cho-Table 1
Changes in overall LDL particle charge (relative electrophoretic
mobility, REM; native LDL = 1), on treatment with 10 mM glycolal-
dehyde in the absence or presence of the speciﬁed inhibitors for 7 days
at 37 C
REM
Incubation control (EDTA) 1.5 + 0.1
10 mM glycolaldehyde (GA) 4.3 + 0.2#
GA + 10 mM carnosine 3.1 + 0.4*,#
GA + 10 mM histidine 3.7 + 0.4*,#
GA + 10 mM b-alanine 4.8 + 0.4#
GA + 10 mM histidine + 10 mM b-alanine 3.4 + 0.7*,#
Data (n = 4–5) are means ± S.D. #P < 0.001 compared with incubation
control. *P < 0.05 compared with GA.lesterol or cholesteryl esters, or formation of lipid or protein
oxidation products [11,12,19]. The presence of equimolar con-
centrations of carnosine (CN), His, or His + b-Ala, but not b-
Ala alone, decreased particle modiﬁcation with the eﬃcacy of
these agents decreasing in the order CN > His + b-Ala >
His > b-Ala.
3.2. Characterisation and inhibition of foam cell formation
Incubation of HMDM with native or modiﬁed LDL parti-
cles did not signiﬁcantly aﬀect cell viability or cell protein lev-
els (data not shown). With HMDM incubated for 48 h in the
absence of LDL, the total cholesterol levels have been deter-
mined as being between 64 and 74 nmoles/mg cell protein with
less than 3% present as cholesteryl esters [31]. Exposure of
HMDM to 100 lg/mL glycolaldehyde-modiﬁed LDL for
48 h, resulted in a signiﬁcant accumulation of cellular choles-
terol and cholesterol esters; the latter account for ca. 50% of
the measured sterol (Fig. 1). The presence of each of the poten-
tial inhibitors during the LDL modiﬁcation phase signiﬁcantly
inhibited subsequent cholesterol and cholesterol ester accumu-
lation by the HMDMs on exposure to the modiﬁed LDL par-
ticles (Fig. 1). There were no signiﬁcant diﬀerences between theFig. 1. Total cholesterol (top) and percentage cholesteryl esters
(bottom) present in HMDM after incubation with 100 lg/mL of
LDL previously treated with 10 mM glycolaldehyde (GA) ± equimolar
concentrations of inhibitor (carnosine {CN}, histidine {His}, b-alanine
{Ala}). Results are expressed as the means + S.E.M. from 3 to 4
separate experiments each with 3–6 samples per treatment. *P < 0.05
compared with GA alone. The total cellular cholesterol contents for
the GA + His and GA + Ala treatments were signiﬁcantly higher than
controls (LDL + EDTA). The percentage cholesteryl esters for the
GA + His, GA + Ala and GA + His + Ala were signiﬁcantly higher
than in controls.
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cholesterol ester levels was observed with CN. Carnosine, un-
like the other treatments, reduced the percentage of cholesterol
esters present in the cells exposed to glycolaldehyde-modiﬁed
LDL, to levels that were not signiﬁcantly diﬀerent to the con-
trols (cells exposed to non-modiﬁed LDL).4. Discussion
Previous studies have shown that ex vivo treatment of LDL
with reactive aldehydes such as methylglyoxal and glycolalde-
hyde results in LDL modiﬁcations that result in these particles
being taken up, in an unregulated manner, by both murine and
human macrophages, with a resultant intracellular accumula-
tion of cholesterol and cholesteryl esters [11,12,31]. A number
of hydrazine compounds can inhibit these eﬀects of glycolalde-
hyde and methylglyoxal, at concentrations less than or equal
to that of the modifying aldehyde [11]. In the current study,
we investigated whether the dipeptide carnosine, which is pres-
ent in many diets and can be safely taken as a supplement, is
an eﬀective inhibitor of LDL glycation induced by glycolalde-
hyde and subsequent intracellular accumulation of cholesterol
and cholesteryl esters in human macrophages.
Carnosine eﬃciently protects LDL against modiﬁcation, as
demonstrated by the abrogation of the change of overall par-
ticle charge induced by glycolaldehyde. This decrease in LDL
modiﬁcation results in complete protection against the pro-
atherogenic (promotion of intracellular cholesterol and choles-
terol ester accumulation) eﬀects of the aldehyde-modiﬁed
LDL; this is in accord with the data obtained with other car-
bonyl scavenging species such as hydrazines [11]. Carnosine
has been reported previously to both react with aldehydes,
and detoxify aldehyde-modiﬁed proteins (reviewed in
[16,17]). Recently, it has also been shown [22] that low micro-
molar concentrations of carnosine (and one of its constituents,
histidine) can inhibit LDL glycation induced by 6-day expo-
sure to 100 mM glucose.
In plasma, carnosine is rapidly hydrolysed by carnosinase
[23] to its constituent amino acids, His and b-Ala; we therefore
compared the eﬀects of carnosine with these amino acids. All
three compounds were eﬀective in preventing cellular choles-
terol and cholesteryl ester accumulation induced by glycolalde-
hyde-modiﬁed LDL in vitro. The eﬀectiveness of both
carnosine and its constituents is of interest in the light of the
action of carnosinase, and contrasts with previous ex vivo
studies. Thus, His and b-Ala have been reported to have neg-
ligible carbonyl scavenging activity over a 5 h period [17,24–
26]. However, over 24 h, His but not b-Ala prevented modiﬁ-
cation [27]. Over even longer periods (2–17 days), all three
compounds aﬀorded signiﬁcant protection against aldehyde-
mediated protein cross-linking and loss of enzyme activity
[26,28]. The last of these studies is in agreement with the results
obtained here. One interpretation of this apparently conﬂicting
data is that carnosine reacts more rapidly with the modifying
aldehydes than His and b-Ala, but over longer periods these
diﬀerences become insigniﬁcant. Thus, both carnosine and its
constituents may oﬀer protection against protein glycation/gly-
coxidation, if the rate of modiﬁcation is slow. This has poten-
tial biological ramiﬁcations for the protection of short-lived
proteins against modiﬁcation by highly reactive aldehydes,
where only carnosine may be eﬀective, whereas each of thesecomponents may oﬀer protection against slower glycation
reactions (e.g. those induced by glucose).
Interestingly, whilst all three compounds signiﬁcantly inhib-
ited cholesterol and cholesterol ester accumulation, b-Ala did
not induce a signiﬁcant reduction in REM. The greater shift
in REM observed with b-Ala compared with the other inhibi-
tor treatments may represent the formation of an adduct that
contributes to charge modiﬁcation. Notably, the REM values
observed for all the treatments were still signiﬁcantly higher
than for the incubation control. Similar behaviour has been
observed with hydrazines [11]. These observations suggest that
complete inhibition of lipid loading can be achieved without
complete prevention of LDL modiﬁcation, and that all that
is required to prevent lipid loading is reduction of damage be-
low a key threshold related to modiﬁcations of key residues on
apolipoprotein B-100 [29]. This has potentially important ther-
apeutic ramiﬁcations.
The concentration of glycolaldehyde used in this study is
higher than that detected in vivo, with experimental values
for plasma varying from submicromolar to hundreds of micro-
molar, depending on the technique employed [5–7]. However,
irrespective of the absolute levels of these aldehydes, the key
ﬁnding of the current study is that carnosine and its constitu-
ents are eﬀective at equimolar concentrations to the modifying
agent. As plasma levels of up to hundreds of micromolar have
been detected in people taking oral doses of carnosine (as a
supplement or in food or drink) [14,30], our data suggests that
carnosine and its constituents may serve as eﬀective scavengers
of carbonyl compounds and inhibitors of protein glycation
in vivo, and as potential therapeutic agents to inhibit diabe-
tes-induced atherosclerosis.Acknowledgements: Mr. I. Rashid acknowledges receipt of an Austra-
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